One hallmark of cancer is intrinsic or acquired resistance to apoptosis. Surprisingly, recent studies demonstrate that CD95/Fas/Apo1 and p53 upregulated mediator of apoptosis/ PUMA (potent inducers of the death receptor and the mitochondrial apoptotic pathways, respectively) promote tumorigenesis. These findings provide important insights into the multifaceted roles of apoptosis in tumorigenesis.
Apoptosis, or programmed cell death, is a process through which superfluous, ectopic, aged, damaged, unattached or mutated cells are eliminated. This death process is mediated by three pathways: an extrinsic pathway involving cell surface receptors, an intrinsic pathway utilizing mitochondria and the endoplasmic reticulum and an immune pathway mediated by delivery of perforin/granzymes by T or natural killer cells. Failure of cells to undergo an appropriate apoptotic cell death is involved in a variety of human diseases including the autoimmune diseases, neurodegenerative disorders and cancer. It is believed that inhibition of apoptosis participates in the initial stages of carcinogenesis. Moreover, chemotherapy resistance may be coupled to resistance to apoptosis induction. Still, a dirty little secret of cancer biologists is that the profoundly apoptosis deficient animals with dual Bax/ Bak knockouts do not have increased numbers of spontaneous tumors (Lindsten and Thompson, 2006) .
Recently, the CD95 receptor, a potent inducer of apoptotic cell death, has been demonstrated to be an important promoter of tumorigenesis in various tumor types (Chen et al., 2010) . CD95 (also called Fas or APO-1) is a prototypical death receptor that regulates tissue homeostasis, primarily within the immune system, through the induction of apoptosis. CD95 induces apoptosis by forming a death-inducing signaling complex at the receptor that contains Fas-associated death domain, caspase-8 and the caspase-8 regulator (Figure 1a ). During tumor progression CD95 is frequently downregulated, and cells are rendered apoptosis resistant. Chen et al. used various human tumor cell lines, primary cancer cell lines, and mouse models of spontaneous or damageinduced ovarian and liver cancers to demonstrate that reducing or abolishing CD95 compromises tumor growth without causing cell death. They found that tumor-expressed ligand for CD95 (CD95L) is necessary for tumor promotion in vivo, presumably acting in a cellintrinsic (autocrine) manner. Moreover, the tumorigenic activity of CD95 is mediated by a pathway involving c-Jun N-terminal kinases (JNKs) associated with increased expression of EGR-1 and Fos transcription factors downstream of JNK (Figure 1b ). JNK1-deficient mice are less susceptible to chemical hepatocarcinogenesis. Chemical inhibition of JNK blocks the growth of CD95-expressing tumor cells. The JNK pathway is one of three members of the mitogen-activated protein kinase, promoted by stress and inflammatory signals. CD95 activation may promote the activity of NF-kB, PI3K-AKT and the two other mitogen-activated protein kinase pathways (ERK1/2 and p38) in other models (Peter et al., 2007) . Thus, it is at first difficult to reconcile why CD95 would be needed to promote cancer with other observations related to loss of apoptosis. Moreover, patients suffering from autoimmune lymphoproliferative syndrome, due to defects in the CD95 signaling pathway, frequently develop lymphoid tumors (Ramenghi et al., 2000) , significantly contrasting with Chen's findings (Chen et al., 2010) . These studies suggested that apoptosis can exert tumor-promoting as well as tumor-suppressing functions, in a context and cell type specific manner.
How does CD95 regulate activation of JNK? CD95 ligand-induced JNK activation and CD95-mediated cell death are independent of the death domain associated protein (DAXX) (Villunger et al., 2000) . The Flice inhibitory protein, a caspase-like molecule without proteolytic activity, protects against CD95-induced apoptosis (Scaffidi et al., 1999) . Flice inhibitory protein can suppress autophagy (Lee et al., 2009 ), a process necessary for the degradation of cytoplasmic constituents in the lysosome or for expulsion from the cell. Autophagy, or programmed cell survival, shares several common stimuli and signaling pathways with those of apoptosis (Maiuri et al., 2007) . Autophagy is a tumorsuppression mechanism, yet it enables tumor-cell survival in settings of enhanced stress (Kondo et al., 2005; Mathew et al., 2007; White and DiPaola, 2009 ). Moreover, autophagy can degrade active caspase-8 within tumor cells (Hou et al., 2010) . Thus, one possible explanation for the findings would be the presence of a regulatory protein (for example, Flice inhibitory protein), which could be recruited to CD95 and regulate activation of JNK and autophagy that represses the potential pro-apoptotic function of CD95 and thereby promote tumor initiation.
The p53 pathway mediates the host response to both metabolic and therapeutic stress. The p53 upregulated modulator of apoptosis (PUMA) is a Bcl-2 homology 3-only Bcl-2 family member (Villunger et al., 2003) and a critical mediator of p53-dependent and -independent apoptosis induced by genotoxic stress and other stimuli (Nakano and Vousden, 2001; Yu et al., 2001; Jeffers et al., 2003) . PUMA activates Bax/Bak indirectly by relieving the inhibition of anti-apoptotic Bcl-2 family proteins to promote mitochondrial dysfunction and release of the mitochondrial apoptogenic proteins (Figure 1c) . Moreover, both PUMA-and Bax-induced autophagy contribute to generating the bioenergetics profile necessary to sustain apoptosis (Yee et al., 2009 ). PUMA expression is frequently downregulated in melanoma and Burkitt lymphomas. It is now widely accepted that PUMA ablation or inhibition leads to apoptosis deficiency, underlying the increased risk for cancer development and therapeutic resistance. Surprisingly, PUMA-deficient mice but not p53-or the Bcl-2 homology 3-only protein Noxa-deficient mice demonstrate a lower incidence of lymphoma following exposure to g-irradiation radiotherapy (RT) (Labi et al., 2010; Michalak et al., 2010) . In contrast, loss of PUMA did not reduce spontaneous tumorigenesis or extend lifespan, suggesting that RT injury is necessary to unmask this unexpected tumor-suppressive process in PUMA-deficient mice. Furthermore, Labi et al. demonstrated that loss of PUMA prevented apoptosis of hematopoietic stem/progenitor cell (HSC) and compensatory proliferation following RT, which contributed to genomic integrity and prevention of tumor formation. Moreover, Michalak et al. found that leukocyte depletion by dexamethasone restores RT-induced thymic lymphoma development in PUMA-deficient mice. These findings suggest that both a reduction/expansion of hematopoietic stem/progenitor cell numbers and death of leukocytes are required for PUMA-mediated DNA damage associated lymphoma development (Figure 1d ). Somewhat paradoxically, loss of PUMA conversely accelerates c-Myc-induced lymphomagenesis, as well as chemical-mediated intestinal tumorigenesis in mice (Hemann et al., 2004; Michalak et al., 2009; Qiu et al., 2009) . c-Myc controls the balance between hematopoietic stem/progenitor cell self-renewal and differentiation The prototypical DAMP, high-mobility group box 1 protein (HMGB1) binds to several receptors including the receptor for advanced glycation end products (RAGE) and sustains inflammation, cell proliferation and autophagy, which in turn promote tumor growth. HMGB1 itself within the cytosol promotes displacement of Beclin 1 from its complex with Bcl-2 and promotes autophagy and apoptosis resistance. AIF, apoptosis-inducing factor; FADD, Fas-associated death domain.
Cellular death promotes cancer development D Tang et al (Wilson et al., 2004) . This has important consequences for considering effective anti-cancer therapies such as RT or targeting oncogenes (for example, c-Myc) that mediate tumor formation, which are significantly different following loss of PUMA. One possible explanation for these findings has not been deeply considered, and that is the emergent differences in the tumor microenvironment following anti-cancer therapy or oncogene expression. The tumor microenvironment refers to a variety of unique properties of the stromal tissues acquired following interaction with the tumor. RT and most chemotherapeutic agents promote injury and resultant necrosis, leading to release of soluble mediators collectively referred to as damage-associated molecular pattern molecules (DAMPs) (Tesniere et al., 2008) . These so-called DAMPs can have either a pro-tumor or an anti-tumor effect depending on the timing during carcinogenesis, the tumor type, the individual tissue microenvironments, and expression of various signaling receptors. The prototypical DAMP, high-mobility group box 1 protein (HMGB1) is released during autophagy, late apoptosis in the absence of early phagocytosis, and necrosis (Scaffidi et al., 2002; Liu et al., 2010; Tang et al., 2010a, b) . Overexpression of HMGB1 is associated with each of the reported hallmarks of cancer including unlimited replicative potential, ability to develop blood vessels (angiogenesis), evasion of apoptosis, self-sufficiency in growth signals, insensitivity to inhibitors of growth, inflammation, tissue invasion and metastasis (Tang et al., 2010c) . Moreover, HMGB1 promotes stem cell migration and proliferation, and recruitment of acute inflammatory cells including macrophages and neutrophils (Lotze and Tracey, 2005; Tang et al., 2010d) . One of the HMGB1 receptors, receptor for advanced glycation end products, has been implicated in tumorigenesis, metastasis, apoptosis and autophagy (Taguchi et al., 2000; Gebhardt et al., 2008; Kang et al., 2010) . Thus DAMPs and the associated DAMP receptors within the tumor microenvironment are an attractive target for improving cancer therapy and possibly, for cancer prevention (Figure 1e ).
These somewhat paradoxical findings provide important insights into the multifaceted roles of pro-apoptotic genes such as CD95 and PUMA in the setting of tumorigenesis and suggest an important emergent role for DAMPs and their receptors. Anti-cancer agents designed to mimic the functions of CD95 or PUMA may thus surprisingly promote formation of secondary tumors. In addition, how cells die becomes critically important in considering how death itself stimulates cancer formation and is suitable for additional study and clinical investigation. Additional studies are required to identify the regulatory factors that provide switches that convert anti-tumor to pro-tumor activity and to understand the complex interplay between apoptosis and autophagy.
